Furthermore, the most commonly used semiquantitative indicator of PET/CT is the maximum standardized uptake value (SUVmax), and positron nuclide-labeled PSMA inhibitors have been used to evaluate primary and metastatic lesions in patients with medium-high-risk prostate cancer (13, 14). The gene discussed is FOLH1; the disease is prostate carcinoma.